CompletedPhase 2

Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts

Egypt39 participantsStarted 2017-07-01

Plain-language summary

The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.

Who can participate

Age range9 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Chronic multiple cutaneous Exclusion Criteria: * Hypersensitivity to Candida antigen * Fever * Immunosuppressive disorders * Previous wart therapy in the last month

What they're measuring

Resolution of warts

Timeframe: 12 weeks

Trial details

NCT IDNCT04399577

SponsorZagazig University

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2019-03-03

View on ClinicalTrials.gov More Warts trials